Marilyn C. Olson

1.5k total citations · 1 hit paper
24 papers, 1.1k citations indexed

About

Marilyn C. Olson is a scholar working on Molecular Biology, Epidemiology and Oncology. According to data from OpenAlex, Marilyn C. Olson has authored 24 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Epidemiology and 5 papers in Oncology. Recurrent topics in Marilyn C. Olson's work include Cervical Cancer and HPV Research (5 papers), Hepatitis B Virus Studies (5 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Marilyn C. Olson is often cited by papers focused on Cervical Cancer and HPV Research (5 papers), Hepatitis B Virus Studies (5 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Marilyn C. Olson collaborates with scholars based in United States and Venezuela. Marilyn C. Olson's co-authors include M. Celeste Simon, Edward W. Scott, Andrew A. Hack, Gloria H. Su, Daniel G. Tenen, John B. Kisiel, Tsetska Takova, Victor I. Lyamichev, Hatim T. Allawi and Jorge Garcés and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Marilyn C. Olson

23 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening

2024 80 citations Thomas F. Imperiale, Kyle Porter et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marilyn C. Olson United States	14	466	285	264	177	156	24	1.1k
Matthew J. Ferber United States	14	370 0.8×	268 0.9×	166 0.6×	173 1.0×	66 0.4×	26	1.0k
Carolina Armengol Spain	18	486 1.0×	211 0.7×	140 0.5×	172 1.0×	172 1.1×	32	940
Hui Xing China	19	536 1.2×	169 0.6×	266 1.0×	168 0.9×	116 0.7×	44	947
Alvin H.K. Cheung Hong Kong	23	870 1.9×	209 0.7×	394 1.5×	433 2.4×	147 0.9×	44	1.6k
Cécile Godard France	19	1.6k 3.3×	247 0.9×	507 1.9×	393 2.2×	148 0.9×	33	2.3k
Yang Wu China	20	513 1.1×	105 0.4×	319 1.2×	301 1.7×	189 1.2×	73	1.2k
Sunil Suchindran United States	15	393 0.8×	474 1.7×	440 1.7×	208 1.2×	126 0.8×	30	1.6k
Xiaomin Liu China	16	320 0.7×	150 0.5×	108 0.4×	63 0.4×	298 1.9×	65	1.1k
Chia‐Hui Lin Taiwan	18	453 1.0×	129 0.5×	70 0.3×	74 0.4×	113 0.7×	71	1.0k

Countries citing papers authored by Marilyn C. Olson

Since Specialization

Citations

This map shows the geographic impact of Marilyn C. Olson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marilyn C. Olson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marilyn C. Olson more than expected).

Fields of papers citing papers by Marilyn C. Olson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marilyn C. Olson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marilyn C. Olson. The network helps show where Marilyn C. Olson may publish in the future.

Co-authorship network of co-authors of Marilyn C. Olson

This figure shows the co-authorship network connecting the top 25 collaborators of Marilyn C. Olson. A scholar is included among the top collaborators of Marilyn C. Olson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marilyn C. Olson. Marilyn C. Olson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Imperiale, Thomas F., et al.. (2024). Algorithm Development and Early Performance Evaluation of a Next-Generation Multitarget Stool DNA Screening Test for Colorectal Cancer. SHILAP Revista de lepidopterología. 3(6). 740–748. 8 indexed citations

Imperiale, Thomas F., Kyle Porter, Marilyn C. Olson, et al.. (2024). Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening. New England Journal of Medicine. 390(11). 984–993. 80 indexed citations breakdown →

Itzkowitz, Steven H., et al.. (2023). Assessment of Stool DNA Markers to Detect Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: A Multi-site Case-control Study. Journal of Crohn s and Colitis. 17(9). 1436–1444. 3 indexed citations

Imperiale, Thomas F., et al.. (2023). S354 Performance Evaluation of a Next-Generation Multitarget Stool DNA (mt-sDNA) Screening Test for Colorectal Cancer (CRC). The American Journal of Gastroenterology. 118(10S). S256–S257.

Chalasani, Naga, Kyle Porter, Abhik Bhattacharya, et al.. (2021). Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology. 20(1). 173–182.e7. 107 indexed citations

Chalasani, Naga, Abhik Bhattacharya, Marilyn C. Olson, et al.. (2020). A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology. 19(12). 2597–2605.e4. 99 indexed citations

Bradley, Paul, Vishaal Mehra, Keith Vrbicky, et al.. (2017). Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility. Journal of Psychiatric Research. 96. 100–107. 146 indexed citations

Olson, Marilyn C., Alejandra Maciel, Juan‐Sebastian Saldivar, et al.. (2017). Clinical Impact of Pharmacogenetic-Guided Treatment for Patients Exhibiting Neuropsychiatric Disorders. The Primary Care Companion For CNS Disorders. 19(2). 24 indexed citations

Bartholomew, Deborah, Ronald D. Luff, Neil B. Quigley, Michelle Curtis, & Marilyn C. Olson. (2011). Analytical performance of Cervista® HPV 16/18 genotyping test for cervical cytology samples. Journal of Clinical Virology. 51(1). 38–43. 24 indexed citations

10.

Quigley, Neil B., et al.. (2011). Rate of detection of high-risk HPV with two assays in women≥30years of age. Journal of Clinical Virology. 52(1). 23–27. 11 indexed citations

11.

Einstein, Mark H., Mark G. Martens, Francisco García, et al.. (2010). Clinical validation of the Cervista® HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecologic Oncology. 118(2). 116–122. 84 indexed citations

12.

Day, Stephen, Angela Hudson, Andrea Mast, et al.. (2009). Analytical performance of the Investigational Use Only Cervista™ HPV HR test as determined by a multi-center study. Journal of Clinical Virology. 45. S63–S72. 51 indexed citations

13.

Olson, Marilyn C., et al.. (2004). Invader Assay for RNA Quantitation. Humana Press eBooks. 258. 53–70. 3 indexed citations

14.

Allawi, Hatim T., James E. Dahlberg, Elsebet Lund, et al.. (2004). Quantitation of microRNAs using a modified Invader assay. RNA. 10(7). 1153–1161. 147 indexed citations

15.

Berggren, W. Travis, Tsetska Takova, Marilyn C. Olson, et al.. (2002). Multiplexed Gene Expression Analysis Using the Invader RNA Assay with MALDI-TOF Mass Spectrometry Detection. Analytical Chemistry. 74(8). 1745–1750. 13 indexed citations

16.

Eis, Peggy S., Marilyn C. Olson, Tsetska Takova, et al.. (2001). An invasive cleavage assay for direct quantitation of specific RNAs. Nature Biotechnology. 19(7). 673–676. 52 indexed citations

17.

Fisher, Robert C., Marilyn C. Olson, Jagan M.R. Pongubala, et al.. (1998). Normal Myeloid Development Requires Both the Glutamine-Rich Transactivation Domain and the PEST Region of Transcription Factor PU.1 but Not the Potent Acidic Transactivation Domain. Molecular and Cellular Biology. 18(7). 4347–4357. 44 indexed citations

18.

Simon, M. Celeste, et al.. (1996). Terminal Myeloid Gene Expression and Differentiation Requires the Transcription Factor PU.1. Current topics in microbiology and immunology. 211. 113–119. 30 indexed citations

19.

Olson, Marilyn C., Edward W. Scott, Andrew A. Hack, et al.. (1995). PU.1 is not essential for early myeloid gene expression but is required for terminal myeloid differentiation. Immunity. 3(6). 703–714. 168 indexed citations

20.

Romano, Egidio, et al.. (1994). Treatment of ABO Hemolytic Disease with Synthetic Blood Group Trisaccharides. Vox Sanguinis. 66(3). 194–199. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact